Investor Relations NEWS

2012.04.23 Holiday closure of ReproCELL headquarters

ReproCELL headquarters in Japan closes on the dates below, for Japanese spring holiday season. April 30th May […]

2012.01.14 Headquarters moved

ReproCELL headquarters has moved to a new address. KDX Shin-Yokohama 381 Bldg. 9F 3-8-11,Shin-Yokohama, Kohoku […]

2011.12.18 ReproCELL Licensed Commercialization Right on Human iPS Cell Derived Hepatocytes – Expected Launch in Q2 2012

YOKOHAMA, Japan, December 15, 2011 – ReproCELL, Inc. (CEO: Chikafumi Yokoyama PhD) announces today that […]

2011.01.05 ReproCELL to Enter Collaborative R&D on Human iPS Cell Derived Hepatocytes

ReproCELL announces today that it will start a collaboration with the National Institute of Biomedical Innovat […]

2010.09.01 ReproCELL announces new line of products in neuronal research using human iPS cells

Since April 2009, ReproCELL has been manufacturing iPS cell-derived cardiomyocytes for drug toxicity testing a […]

2009.04.30 Cellartis and ReproCELL Sign Agreement to Provide CardioToxicity screening service using hESC derived Cardiomyocytes

Cellartis AB, a premier provider of stem cell derived products and technologies, and ReproCELL, a Japanese bio […]

2009.04.16 New Stem Cell Technology to Improve Drug Safety

iPS cardiomyocytes used in a novel cardiotoxicity assay Drug side effects are a major problem for the drug ind […]